The impact of HIV antiretroviral therapy (ART) on immune dysregulation associated with hepatitis C virus (HCV)/HIV coinfection is incompletely understood. We serially assessed monocyte activation (neopterin, sCD14, and sCD163) and T cell activation (HLA-DR, CD38) and immune exhaustion [program cell death protein 1 (PD1), TIGIT] in HIV/HCV-coinfected individuals who participated in a randomized trial performed in Vietnam designed to assess the hepatotoxicity of raltegravir (RAL)- versus efavirenz (EFV)-based therapy when used as first-time ART in combination with tenofovir disoproxil fumarate and emtricitabine. Baseline pre-ART values were compared with those from ART-naive HIV-monoinfected and HIV-seronegative individuals. Before ART, HIV/HCV-coinfected individuals had higher levels of neopterin, sCD14, and sCD163, and increased frequencies of CD38⁺HLA-DR⁺, PD1⁺, and TIGIT⁺ CD4 and CD8 T cells compared with ART-naive HIV-monoinfected or HIV-seronegative individuals (all p < .01).

中文翻译：

---

越南 HIV/HCV 合并感染者接受拉替拉韦与依非韦伦治疗后 72 周内的免疫变化


HIV 抗逆转录病毒治疗 (ART) 对丙型肝炎病毒 (HCV)/HIV 合并感染相关免疫失调的影响尚不完全清楚。我们连续评估了 HIV/HCV 合并感染个体的单核细胞激活（新蝶呤、sCD14 和 sCD163）和 T 细胞激活（HLA-DR、CD38）和免疫耗竭 [程序细胞死亡蛋白 1 (PD1)、TIGIT]。在越南进行的随机试验，旨在评估拉替拉韦 (RAL) 与依非韦伦 (EFV) 为基础的治疗在首次 ART 与富马酸替诺福韦二吡呋酯和恩曲他滨联合使用时的肝毒性。将 ART 前的基线值与未接受 ART 的 HIV 单一感染者和 HIV 血清阴性个体的基线值进行比较。在 ART 之前，与未接受 ART 的 HIV 单一感染者相比，HIV/HCV 合并感染者的新蝶呤、sCD14 和 sCD163 水平较高，并且 CD38 ⁺ HLA-DR ⁺ 、 PD1 ⁺ 、TIGIT ⁺ CD4 和 CD8 T 细胞的频率增加或 HIV 血清阴性个体（所有p < .01）。